A timeline for Parkinson's disease, Parkinsonism Relat Disord, vol.16, issue.2, pp.79-84, 2010. ,
Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, vol.24, pp.197-211, 2003. ,
Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?, Ann Neurol, vol.32, pp.88-93, 1992. ,
Missing pieces in the Parkinson's disease puzzle, Nat Med, vol.16, pp.653-61, 2010. ,
Prion-like propagation of pathology in Parkinson disease, Handb Clin Neurol, vol.153, pp.321-335, 2018. ,
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease, Neuron, vol.90, issue.4, pp.675-91, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01348875
Neuroinflammation in Parkinson's disease: a target for neuroprotection?, Lancet Neurol, vol.8, pp.382-97, 2009. ,
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, vol.38, issue.8, pp.1285-91, 1988. ,
Brain infiltration of CD4 lymphocytes contributes to neurodegeneration in Parkinson's disease model, J Clin Invest, vol.119, pp.182-92, 2008. ,
Changes in cytokines and neurotrophins in Parkinson's disease, J Neural Trans, issue.60, pp.277-290, 2000. ,
Microglial activation and dopamine terminal loss in early Parkinson's disease ,
, Ann Neurol, vol.57, issue.2, pp.168-75, 2005.
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease, Neurobiol Dis, vol.21, issue.2, pp.404-416, 2006. ,
Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study, Ann Nucl Med, vol.30, issue.8, pp.579-87, 2016. ,
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease, Nat Genet, vol.42, pp.781-786, 2010. ,
Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease, FASEB J, vol.377, pp.500-502, 2003. ,
Association of Parkinson disease with structural and regulatory variants in the HLA region, Am J Hum Genet, vol.93, issue.5, pp.984-93, 2013. ,
Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control Study, NPJ Parkinsons Dis, vol.1, p.15002, 2015. ,
A pathway-based analysis provides additional support for an immunerelated genetic susceptibility to Parkinson's disease, Hum Mol Genet, vol.22, issue.5, pp.1039-1088, 2013. ,
Genome-wide pathway-based association analysis identifies risk pathways associated with Parkinson's disease, Neuroscience, vol.340, pp.398-410, 2017. ,
Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases, Ann Clin Transl Neurol, vol.3, issue.12, pp.924-933, 2016. ,
Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes, Science, vol.344, issue.6183, pp.519-542, 2014. ,
Redefining Parkinson's Disease Pathogenesis, Trends Neurosci, vol.42, issue.1, pp.4-13, 2019. ,
Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis, JAMA Neurol, vol.73, issue.11, pp.1316-1324, 2016. ,
,
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD), Mov Disord, 2016. ,
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients, Neurosci Lett, vol.202, pp.17-20, 1995. ,
Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factoralpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease, Neurosci Lett, vol.211, pp.13-16, 1996. ,
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease, Neurosci Lett, vol.193, pp.129-132, 1995. ,
Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment, Brain Behav Immun, vol.33, pp.183-189, 2013. ,
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One, vol.8, p.71634, 2013. ,
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations, JAMA Neurol, 2013. ,
Inflammatory dysregulation of blood monocytes in Parkinson's disease patients, Acta Neuropathol, vol.128, issue.5, pp.651-63, 2014. ,
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease, J Neuroimmune Pharmacol, vol.7, issue.4, pp.927-965, 2012. ,
Lindestam Arlehamn CS, Sette A. T cells from patients with Parkinson's disease recognize ?-synuclein peptides, Nature, vol.546, issue.7660, pp.656-661, 2017. ,
?-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease, Nature Comm, 2020. ,
PET: quantification of neuroinflammation and a monitor of antiinflammatory treatment in Parkinson's disease?, Parkinsonism Relat Disord, vol.16, issue.1, pp.57-66, 2010. ,
Microglial activation in Parkinson's disease using [18F]-FEPPA, J Neuroinflammation, vol.14, issue.1, p.8, 2017. ,
PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R), Proc Natl Acad Sci, vol.116, issue.5, pp.1686-1691, 2019. ,
Inflammation and ?-synuclein's prion-like behavior in Parkinson's disease--is there a link?, Mol Neurobiol, vol.47, issue.2, pp.561-74, 2013. ,
Abnormalities of age-related T cell senescence in Parkinson's disease, J Neuroinflammation, vol.15, p.166, 2018. ,
Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism, Proc Natl Acad Sci U S A, vol.108, pp.6632-6639, 2011. ,
Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease, Acta Neuropathol, vol.116, pp.47-55, 2008. ,
Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease, J Neuroinflammation, vol.11, p.86, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-00990645
Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease, Sci Rep, vol.3, p.1393, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01610346
Synuclein activates microglia in a model of Parkinson's disease, Neurobiol Aging, vol.29, issue.11, pp.1690-701, 2008. ,
MHCII is required for ?-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration, J Neurosci, vol.33, issue.23, pp.9592-600, 2013. ,
,
, Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease, J Neurochem, vol.104, pp.1504-1529, 2008.
Nitrated ?-synucleininduced alterations in microglial immunity are regulated by CD4+ T cell subsets, J Immunol, vol.182, pp.4137-4186, 2009. ,
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons, PLoS One, vol.3, issue.1, p.1376, 2008. ,
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease, Cell, vol.167, issue.6, pp.1469-1480, 2016. ,
Oral and nasal microbiota in Parkinson's disease, Parkinsonism Relat Disord, vol.38, pp.61-67, 2017. ,
, Acta Neuropathol, vol.131, issue.3, pp.379-91, 2016.
Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes, J Neuroinflammation, vol.14, p.60, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01493135
Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis, Free Radic Biol Med, vol.115, pp.80-91, 2018. ,
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration, Nat Neurosci, vol.14, issue.10, pp.1227-1262, 2011. ,
Macrophages at CNS interfaces: ontogeny and function in health and disease, Nat Rev Neurosci, 2019. ,
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease, J Neurosci, vol.22, issue.5, pp.1763-71, 2002. ,
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease, J Neurochem, vol.82, issue.3, pp.615-639, 2002. ,
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration, Ann Neurol, vol.54, issue.5, pp.599-604, 2003. ,
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Ann Neurol, 1999. ,
Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease, Exp Neurol, vol.300, pp.179-187, 2018. ,
,
Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson's Disease, Cell Stem Cell, vol.23, issue.1, pp.123-131, 2018. ,
The glymphatic pathway in neurological disorders, Lancet Neurol, vol.17, issue.11, pp.1016-1024, 2018. ,
Potential Modes of Intercellular ?-Synuclein Transmission, Int J Mol Sci, vol.18, issue.2, 2017. ,
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo ,
, Ann Neurol, vol.57, issue.2, pp.176-185, 2005.
Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet, vol.353, pp.981-983, 1999. ,
Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian, J Neural Transm (Vienna), vol.112, issue.9, pp.1237-1285, 2005. ,
,
, Increased CSF biomarkers of angiogenesis in Parkinson disease, Neurology, vol.85, issue.21, pp.1834-1876, 2015.
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease, Neuroimage, vol.61, issue.1, pp.228-267, 2012. ,
Novel biomarker signatures for idiopathic REM sleep behavior disorder: A proteomic and system biology approach, Neurology, vol.91, issue.18, pp.1710-1715, 2018. ,
Peripheral Blood Inflammatory Cytokines in Idiopathic REM Sleep Behavior Disorder, Mov Disord, vol.34, issue.11, pp.1739-1744, 2019. ,
,
, Parkinson's disease, Lewy body disease, and Alzheimer's disease, Int J Geriatr Psychiatry, vol.34, issue.8, pp.1244-1250, 2019.
Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study, Lancet Neurol, vol.16, issue.10, pp.789-796, 2017. ,
Use of ibuprofen and risk of Parkinson disease, Neurology, vol.76, pp.863-872, 2011. ,
Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis, vol.74, pp.995-1002, 2010. ,
NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies, Drugs Aging, vol.26, issue.9, pp.769-79, 2009. ,
Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis. Medicine (Baltimore), vol.97, p.12172, 2018. ,
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease, Neurology, vol.66, issue.5, pp.664-71, 2006. ,
Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease, JAMA Neurol, vol.75, issue.8, pp.939-946, 2018. ,
Innate and adaptive immune responses in Parkinson's disease, Progress in Brain Research, 2020. ,
An essay on the shaking palsy, Etienne Hirsch B. Review and Critique, p.1817 ,
,
Standaert is a member of the faculty of the University of Alabama at Birmingham and is supported by endowment and University funds. Dr. Standaert is an investigator in studies funded by Abbvie ,
, Alabama Department of Commerce, the Department of Defense, and NIH grants P01NS087997, P50NS108675, R25NS079188, P2CHD086851, P30NS047466, and T32NS095775. He has a clinical practice and is compensated for these activities through the University of Alabama Health Services Foundation, addition, since, 2019.